论文部分内容阅读
本文观察国产小剂量人白细胞干扰素(IFN)治疗HBeAg阳性的慢性乙型肝炎(慢乙肝),并与对照组作疗效对比观察,现将结果报告如下: 材料和方法观察病例系1988年3月～1991年1月的HBeAg阳性的住院病人(其中12例在专科门诊治疗),共126例;肝功能均有不同程度的异常。按1984年南宁肝炎会议诊断标准。治疗组72例中慢活肝13例、慢迁肝59例,男54例,女18例,男女之比为3:1;年龄6～54岁,平均29.3±1.8岁,病程6个月～11年,平均2.5±3.2年。对照组54例,慢活肝9例、慢迁肝45例,男42例,女12例,男女之比为3.5:1;年龄3～61岁,平均26.2±1.3岁,病程6个月～6年,平均2.7±2.8年。治疗方法:护肝疗法两组相同(应用维生素,联
This article observed the domestic small doses of human leukocyte interferon (IFN) treatment of HBeAg-positive chronic hepatitis B (chronic hepatitis B), and compared with the control group efficacy comparison, the results are reported as follows: Materials and methods observed cases Department of March 1988 ~ In January 1991 HBeAg-positive inpatients (of which 12 were treated in specialist clinics), a total of 126 cases; liver function has varying degrees of abnormalities. According to the 1984 Nanning hepatitis meeting diagnostic criteria. The treatment group 72 cases of slow living liver in 13 cases, 59 cases of slow migration of liver, 54 males and 18 females, male to female ratio of 3: 1; aged 6 to 54 years, mean 29.3 ± 1.8 years, duration of 6 months ~ 11 years, an average of 2.5 ± 3.2 years. The control group of 54 cases, slow-living liver in 9 cases, 45 cases of slow-moving liver, 42 cases of male and 12 females, male to female ratio was 3.5: 1, aged 3 to 61 years, mean 26.2 ± 1.3 years, duration 6 months ~ 6 years, an average of 2.7 ± 2.8 years. Treatment: Liver therapy the same two groups (using vitamins, joint